Executive Board

Prof. dr. Matthijs Verhage (chair)– Vrije Universiteit Amsterdam & Amsterdam UMC

Prof. dr. Nael Nadif Kasri (Vice chair)– Radboudumc

Dr. Claudia Persoon (project manager) – Vrije Universiteit Amsterdam & Amsterdam UMC

Steering committee

Dr. Eline Bunnik – Erasmus MC

Prof. Dr. Floris Rutjes – Radboud Universiteit

Prof. Dr. Hilgo Bruining – Amsterdam UMC

Dr. Klaus Linkenkaer Hansen – Vrije Universiteit Amsterdam

Dr. Monica Frega – Universiteit Twente

Dr. Niels Cornelisse – Vrije Universiteit Amsterdam

Dr. Niels Tas – Universiteit Twente

Prof. Dr. Tjitske Kleefstra – Radboudumc

BRAINmodel PhD students

Shilpa Anand

PhD candidate at Amsterdam UMC

Investigation of EEG biomarkers to study the effect of Bumetanide, using an N=1 study design, in the treatment of neurodevelopmental disorders (NDDs).

WP2: D2.3; WP5: T5.2 and T5.3 (see below).

Additya Sharma

PhD candidate at VU University

Computational models and EEG tools for understanding how aberrant IPSC properties relate to clinical manifestations

WP2: T2.1, T2.3, and T2.4; D2.3.

Arianne Bouman

PhD candidate at Radboud UMC

Clinical phenotyping and following excitation/inhibition ratio homeostasis in Chromatin- and SNAREopathies

WP1: T1.1 and T1.2; D1.2 and D1.2
WP2: T2.1, T2.3 and T2.4
WP5: T5.1, T5.2, and T5.3; D5.1, D5.2, and D5.3

Nina Doorn

PhD candidate at University Twente

Integration of cellular, network, and EEG data

WP2: T2.2, T2.3, and T2.4; D2.2 and D2.3

Sietske van Till

PhD candidate at Erasmus MC

The ethical aspects of using patient-own stem cell-derived neuronal cell models in research and clinical care of children with monogenetic neurodevelopmental disorders.

WP1: T1.1, T1.2, and T1.3; D1.1, D1.2, D1.3 and D1.4

Ellen van den Berg

PhD candidate at Radboud University

Novel compounds for SNAREopathies and Chromatinopathies.

WP4: T4.2, D4.2

Affiliated researchers

Chantal Bijnagte-Schoenmaker – Radboudumc

Dr. Dirk Schubert – Radboud Universiteit

Eva Haspels – Amsterdam UMC

Gianina Cristian – Radboudumc en Amsterdam UMC

Dr. Jennifer Ramautar – Amsterdam UMC

Dr. Jonne Doorduin –  Radboudumc

Dr. Joyce Geelen – Radboudumc

Lara Janssen – Vrije Universiteit Amsterdam

Lisa Geertjens – Amsterdam UMC

Maaike van Boven – Vrije Universiteit Amsterdam

Miriam Öttl – Vrije Universiteit Amsterdam

Dr. Ruud Toonen – Vrije Universiteit Amsterdam

Torben van Voorst – Vrije Universiteit Amsterdam

WP1 –  Address ethical issues in IPSC-based approaches and develop ethics guidance
T 1.1    Understand patients’ and patient families’ perspectives of IPSC technology.
T 1.2    Understand clinicians’ perspectives & preferences regarding IPSC technology.
T 1.3    Develop ethics guidance for research & clinical implementation of IPSC technology.

D 1.1    Report on qualitative studies of patients’, families’ and clinicians’ perspectives and preferences.
D 1.2    Develop and distribute patient, patient family and clinician educational materials (animated videos). 
D 1.3    Make innovative conceptual contributions to ethics literature on IPSC technology in NDD research.
D 1.4    Offer practical ethics guidance on expected and emerging ethical issues associated with clinical implementation of IPSC technology in NDDs.
WP2 – Employ our IPSC-based assays to characterize aberrant synaptic/network properties, and relate these to E/I-sensitive EEG biomarkers and clinical manifestations for selected mNDDs
T 2.1    Extend clinical cohort and generation of iPSCs
T 2.2    Examine E/I disturbances in iPSC-derived neurons and neuronal networks.
T 2.3    Integrate MEA assays with new EEG biomarkers for E/I balance.
T 2.4    Integrate cellular and clinical data.

D 2.1    A well-characterized cohort of iPSC lines deposited at UMC Biobanks and hPSCreg
D 2.2    All patient IPSC derived neurons functional characterized for E/I ratio at the single/network level
D 2.3    Functional E/I quantification based on EEG for enrolled patients.
WP3 – Restore aberrant properties with off-label medication and indicate rational treatments
T 3.1    Select and test compounds to restore aberrant properties in our IPSC models.
D 3.1    Select high-confidence compounds for each mNDD gene.
WP4 – Upscale IPSC-based assays and design new compounds
T 4.1    Develop nano-chip for parallel patch-clamp.
T 4.2    Develop novel compounds.

D 4.1    Up-scaled nanochips and set-up for multiple (3 x 3) site patch-clamp recording
D 4.2    6 Novel compounds selectively targeting SNAREopathies or Chromatinopathies
WP5 – Disseminate BRAINMODEL strategy for other NDDs and as a European standard
T 5.1    Connecting patients and researcher to engage in patient-centered outcomes research.
T 5.2    Demonstrate the applicability to other (m)NDDs.
T 5.3    Assist with the implementation of BRAINMODEL in other academic centers.

D 5.1    Impact plan for knowledge utilization and annual panel discussions
D 5.2    Awareness of the BRAINMODEL strategy in international NDD centers/clinics
D 5.3    Promoted impact of BRAINMODEL strategy for cell-based medicine